Torisel temsirolimus
替西罗莫司
Drug Class
mTOR inhibitormTOR 抑制剂
Mechanism
Binds to intracellular FKBP-12, forming a complex that inhibits mTOR kinase activity and arrests cell cycle progression in the G1 phase while blocking angiogenesis.在细胞内与FKBP-12蛋白特异性结合，形成抑制mTOR激酶活性的复合物，从而将细胞周期阻断在G1期，并减少促进新生血管生成的因子产生。
Approved Indication
Advanced renal cell carcinoma, per its FDA approval.根据美国FDA批准，适用于晚期肾细胞癌的治疗。
What This Means For Patients
Torisel is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.Torisel（替西罗莫司）目前未通过中国大陆零售药房渠道销售。优健云可协助安排购买渠道，药品由香港采购发货；如有需要，可协调来华后的临床用药支持。具体供应及患者适用性以医疗预检评估为准。
Regulatory Approvals
- FDA — Approved (2007) — Sources
Pivotal Clinical Evidence
- Global ARCC — Hudes et al., N Engl J Med 2007 (NCT00065910) — Sources